These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 9278332)

  • 41. Naloxone/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses.
    Velashjerdi Farahani S; Reza Aghasadeghi M; Memarnejadian A; Faezi S; Shahosseini Z; Mahdavi M
    Pathog Glob Health; 2016 Mar; 110(2):39-47. PubMed ID: 26403975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24.
    Suzue K; Young RA
    J Immunol; 1996 Jan; 156(2):873-9. PubMed ID: 8543845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.
    Chen YL; Chen YS; Hung YC; Liu PJ; Tasi HY; Ni WF; Hseuh PT; Lin HH
    Microbiol Immunol; 2015 Aug; 59(8):483-94. PubMed ID: 26094825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunogenicity of recombinant adeno-asscociated virus type 1 expressing HIV-1 gp120 gene in mice and Rhesus macaques].
    Yu SQ; Feng X; Liu HM; Yang HR; Li HX; Zeng Y
    Bing Du Xue Bao; 2010 Mar; 26(2):115-20. PubMed ID: 20480640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.
    Banerjee K; Andjelic S; Klasse PJ; Kang Y; Sanders RW; Michael E; Durso RJ; Ketas TJ; Olson WC; Moore JP
    Virology; 2009 Jun; 389(1-2):108-21. PubMed ID: 19410272
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo.
    Germann T; Bongartz M; Dlugonska H; Hess H; Schmitt E; Kolbe L; Kölsch E; Podlaski FJ; Gately MK; Rüde E
    Eur J Immunol; 1995 Mar; 25(3):823-9. PubMed ID: 7705414
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Polycation-decorated PLA microspheres induce robust immune responses via commonly used parenteral administration routes.
    Chen X; Wang L; Liu Q; Jia J; Liu Y; Zhang W; Ma G; Su Z
    Int Immunopharmacol; 2014 Dec; 23(2):592-602. PubMed ID: 25466267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct.
    Aggarwal P; Kumar S; Vajpayee M; Seth P
    Viral Immunol; 2005; 18(4):649-56. PubMed ID: 16359231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Th2-Th1 shift with the multiantigenic formulation TERAVAC-HIV-1 in Balb/c mice.
    García-Díaz D; Rodríguez I; Santisteban Y; Márquez G; Terrero Y; Brown E; Iglesias E
    Immunol Lett; 2013 Jan; 149(1-2):77-84. PubMed ID: 23183092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins.
    Albu DI; Jones-Trower A; Woron AM; Stellrecht K; Broder CC; Metzger DW
    J Virol; 2003 May; 77(10):5589-97. PubMed ID: 12719551
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel adjuvant for mucosal immunity to HIV-1 gp120 in nonhuman primates.
    Yoshino N; Lü FX; Fujihashi K; Hagiwara Y; Kataoka K; Lu D; Hirst L; Honda M; van Ginkel FW; Takeda Y; Miller CJ; Kiyono H; McGhee JR
    J Immunol; 2004 Dec; 173(11):6850-7. PubMed ID: 15557179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
    Moore A; McCarthy L; Mills KH
    Vaccine; 1999 Jun; 17(20-21):2517-27. PubMed ID: 10418898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response.
    Villacres-Eriksson M; Behboudi S; Morgan AJ; Trinchieri G; Morein B
    Cytokine; 1997 Feb; 9(2):73-82. PubMed ID: 9071557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Humoral and cellular immunities elicited by HIV-1 vaccination.
    Shiver JW; Davies ME; Perry HC; Freed DC; Liu MA
    J Pharm Sci; 1996 Dec; 85(12):1317-24. PubMed ID: 8961146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stimulation of both humoral and cellular immune responses to HIV-1 gp120 by interleukin-12 in Rhesus macaques.
    van der Meide PH; Villinger F; Ansari AA; Groenestein RJ; de Labie MC; van den Hout YJ; Koornstra WH; Bogers WM; Heeney JL
    Vaccine; 2002 May; 20(17-18):2296-302. PubMed ID: 12009285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
    Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
    Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two mucosal-parenteral schedules to coadminister a multiantigenic formulation against HIV-1 in Balb/c mice.
    Iglesias E; García D; Márquez G; Prieto YC; Sánchez J; Trimiño L; Soria Y; García D
    Int Immunopharmacol; 2012 Mar; 12(3):487-93. PubMed ID: 22240123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
    O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
    Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Formulation of a recombinant HIV-1 polytope candidate vaccine with naloxone/alum mixture: induction of multi-cytokine responses with a higher regulatory mechanism.
    Fathi M; Nezamzadeh R; Abdollahpour-Alitappeh M; Yazdi MH; Khoramabadi N; Mahdavi M
    APMIS; 2021 Aug; 129(8):480-488. PubMed ID: 33539574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.